Isabel Castrejón

1. LINDE, Louise, ØRNBJERG, Lykke M., MIDTBØLL ØRNBJERG, Lykke, HEEGAARD BRAHE, Cecilie, WALLMAN, Johan Karlsson, DI GIUSEPPE, Daniela, ZÁVADA, Jakub, CASTREJÓN, Isabel, DIAZ-GONZALEZ, Federico, ROTAR, Žiga, TOMŠIČ, Matija, et al. Second and third TNF inhibitors in European patients with axial spondyloarthritis : effectiveness and impact of the reason for switching. Rheumatology. 2024, vol. 63, iss. 7, str. 1882-1892, ilustr. ISSN 1462-0332. https://academic.oup.com/rheumatology/advance-article/doi/10.1093/rheumatology/kead494/7279116?login=false, DOI: 10.1093/rheumatology/kead494. [COBISS.SI-ID 166473219]
projekt: Supported by Novartis Pharma AG

2. PONS, Marion, GEORGIADIS, Stylianos, ØSTERGAARD, Mikkel, AHMADZAY, Zohra Faizy, GLINTBORG, Bente, HEBERG, Jette, NYSOM CHRISTENSEN, Sara, RASMUSSEN, Simon Horskjær, GITTE LOFT, Anne, CASTREJÓN, Isabel, ROTAR, Žiga, PERDAN-PIRKMAJER, Katja, et al. Four-year secukinumab treatment outcomes in European real-world patients with axial spondyloarthritis and psoriatic arthritis. Joint bone spine. May 2025, vol. 92, iss. 3,[article no.] 105824, str. 1-13, ilustr. ISSN 1297-319X. https://www.sciencedirect.com/science/article/pii/S1297319X24001350?via%3Dihub, DIRROS, RUL, DOI: 10.1016/j.jbspin.2024.105824. [COBISS.SI-ID 218928131]